Generex Biotechnology has incorporated SIA ‘Generex Biotechnology BALTIC’ in the EU as a wholly-owned subsidiary of Generex.
The purpose of the subsidiary is to harness and develop the local marketplace in the Baltic region and surrounding for the company’s flagship product Generex Oral-lyn and its complementary metabolic disease pipeline products including MetControl, Glucose RapidSpray and the company’s other confectionary products as well as its immunotherapeutic vaccine platform particularly in the influenza application. Generex Baltic will serve as a regulatory arm in this region and benefit from the connection to the European health agency.
Anna Gluskin, president and chief executive officer of Generex, said: We feel that the establishment of this subsidiary will allow the company to untap a part of the world where governments are eager to implement new treatments to growing pandemics both in diabetes and influenzas. The other benefit at out disposal is the fact that Latvia is a member of the European Community which may provide a pathway to the regulatory environment throughout the continent.
Generex Baltic will work closely with the established Generex MENA branch office in Dubai to establish marketing and logistical support for products already available for distribution.